Histamine and interleukin-2 in acute myelogenous leukemia

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 429-438

  Hellstrand, Kristoffer ^a   Mellqvist, Ulf Henrik ^a   Wallhult, Elisabeth ^a   Carneskog, Jan ^a   Kimby, Eva ^b   Celsing, Fredrik ^b   Brune, Mats ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute leukemia; AML; Histamine; IL 2; Immunotherapy; Interleukin 2; NK cells

Indexed keywords

CYTARABINE; HISTAMINE; INTERLEUKIN 2; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BLAST CELL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG POTENTIATION; DRUG TOLERABILITY; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; LEUKEMIA CELL; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0031441799     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058309     Document Type: Review

References (40)

1. Trinchieri, G. (1989). Biology of natural killer cells. Adv. Immunol., 47, 187-376.
2. Rosenberg, S. A., Lotze, M. T. and Muul, L. M. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or interleukin-2 alone. N. Engl. J. Med., 316, 889-897.
3. Rosenberg, S. A., Lotze, M. T., Yang, J. C. and Aebersold, P. M. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210, 474-485.
4. Bukowski, R. M., Goodman, R. and Crawford, E. D. (1989). A phase II study of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol., 7, 477-485.
5. Foa, R. (1996). Interleukin-2 in the management of acute leukemia. Br. J. Haematol, 92, 1-3.
6. MacDonald, D., Jiang, Y. Z. and Gordon, A. A. (1990). Recombinant IL 2 for acute myeloid leukemia in first complete remission: a pilot study. Leuk. Res., 14, 967-973.
7. Shepherd, J. D., Jacky, E., Grathwohl, A., Helbig, W., Maranchini, D., Zittoun, R., Newland, A., Prentice, A., Selleslag, D., Fey, M., Cavalli, F., Hess, U., Bell, A., Prentice, H. G., Gerhartz, H. H., Mertelsman, R., Fenaux, P., Bosly, A., Ferrant, A., Gluck, S., Michal, S. and Osterwalder, B. (1994). Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukaemia in partial or complete second remission and partial relapse. Br. J. Haematol., S87, 205.
8. Blaise, D., Attal, A., Pico, J. L., Reiffers, J., Stoppa, A. M., Bellanger, C., Molina, L., Nedellec, G., Vernant, J. P., Legros, M., Gabus, R., Huguel, F., Brandely, M., Hercend, T., Olive, D. and Maranchini, D. (1996). Impact of recombinant IL-2 (rIL-2) after autologous BMT in 50 patients with CRI acute leukaemia. Br. J. Haematol., S19, 122.
9. Bergmann, L., Heil, G., Kolbe, K., Lengfelder, E., Puzicha, E., Martin, H., Lohmeyer, J., Mitrou, P. S. and Hoelzer, D. (1995). Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukaemia. Leuk. Lymphoma, 6, 271-279.
10. Brunda, M. J., Bellantoni, D. and Sulich, V. (1987). In vivo anti-tumour activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer, 40, 365-341.
11. Maekawa, R., Kitagawa, T., Koizumi, K., Sato, K. and Homma. M. (1989). Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumours. J. Biol. Response Mod., 8, 676-690.
12. Mulé, J. J., Yang, J. C., Lafreniere, R., Shu, S. and Rosenberg, S. A. (1987). Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2, J. Immunol., 139, 285-299.
13. Lotze, M. T. and Rosenberg, S. A. (1988). Interleukin 2 as a pharmacologic reagent. In: Smith, K. A., (ed.) Interleukin-2. (Academic Press, San Diego.) pp. 237-294.
14. Hellstrand, K., Kjellson, B. and Hermodsson, S. (1991). Monocyte-induced down-modulation of CD16 and CD56 Ag expression on human natural killer cells and its regulation by histamine H2-receptors. Cell. Immunol., 138, 44-54.
15. Hellstrand, K. and Hermodsson, S. (1991). Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand. J. Immunol., 34, 741-752.
16. Hellstrand, K. and Hermodsson, S. (1990). Monocyte-mediated suppression of IL-2-induced NK-cell activation: Regulation by serotonin 5-HT1A receptors. Scand. J. Immunol., 32, 183-192.
17. Hellstrand, K. and Hermodsson, S. (1990). Synergistic NK cell activation by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol., 92, 379-389.
18. Asea, A., Hansson, M., Czerkinsky, C., Hermodsson, S., Strannegård, Ö. and Hellstrand, K. (1996). Histaminergic regulation of the production of IFN-γ by human natural killer cells. Clin. Exp. Immunol., 105, 376-382.
19. Hellstrand, K., Asea, A. and Hermodsson, S. (1994). Histaminergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J. Immunol., 153, 4940-4947.
20. Hansson, M., Asea, A., Ersson, U., Hermodsson, S. and Hellstrand, K. (1996). Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J. Immunol., 156, 42-47.
21. Hansson, M., Asea, A., Hermodsson, S. and Hellstrand, K. (1996). Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis. Scand. J. Immunol., 42, 193-196.
22. Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P. and Kiessling, R. (1996). Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T-cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26, 1308-1313.
23. Matsuda, M., Petersson, M., Lenkei, R., Taupin, J. L., Magnusson, I., Mellstedt, H., Anderson, P. and Kiessling, R. (1995). Alterations in the signal-transducing molecules of T-cells and NK-cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer, 61, 765-772.
24. Allen, C. and Hogg, N. (1987). Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J. Natl. Cancer Inst., 78, 465-470.
25. Brocker, E. B., Zwadlo, G., Suter, L., Brune, M. and Sorg, C. (1987). Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol. Immunother., 25, 81-86.
26. Brune, M. and Hellstrand, K. (1996). Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br. J. Haematol., 92, 620-626.
27. Brune, M., Hansson, M., Mellqvist, U.-H., Hermodsson, S. and Hellstrand, K. (1996). NK-cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur. J. Haematol., 57, 312-319.
28. 2-receptor mediated regulation of human natural killer cell cytotoxicity. J. Immunol., 137, 656-660.
29. Hellstrand, K., Asea, A. and Hermodsson, S. (1990). Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol., 145, 4365-4370.
30. Asea, A., Hermodsson, S. and Hellstrand, K. (1996). Histaminergic regulation of natural killer-cell-mediated clearance of tumor cells in mice. Scand. J. Immunol., 43, 9-15.
31. Hellstrand, K., Naredi, P., Lindnér, P., Lundholm, K., Hermodsson, S., Rudenstam, C.-M., Azstély, M. and fström, L.-O. (1994). Histamine in immunotherapy of advanced melanoma. A pilot study, Cancer Immunol. Immunother., 39, 416-419.
32. Archimbaud, E., Bailly, M. and Doré, J. R (1991). Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance. Br. J. Haematol, 77, 328-234.
33. Lauria, F., Raspadori, D., Rondelli, D., Ventura, M. A. and Foa, R. (1994). In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia, 8, 724-728.
34. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M., Sainty, D., Marit, G., Stoppa, A. M. and Reiffers, J. (1991). High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood., 78, 2182-2187.
35. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Tos, A. G. and Mandelli, F. (1994) Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84, 2158-2163.
36. Cassileth, P. A., Lynch, E., Hines, J. D., Oken, M. M., Mazza, J. J., Bennett, J. M., McGlave, P. B., Edelstein, M., Harrington, D. P. and O'Connell, M. J. (1992). Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79, 1924-1930
37. Vogler, W. R. (1992). Strategies in the treatment of acute myelogenous leukemia. Leuk. Res., 16, 1143-1153.
38. Mastrianni, D. M., Tung, N. M. and Tenen, D. G. (1992). Acute myelogenous leukemia: current treatment and future directions. Am. J. Med., 92, 286-295.
39. Swansbury, G. J., Lawler, S. D., Alimena, G., Arthur, D., Berger, R., Van den Berghe, H., Bloomfield, C. D., de la Chappelle, A., Dewald, G. and Garson, O. M. (1994). Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet. Cytogenet., 73, 1-7.
40. Thalhammer, F., Geissler, K., Jager, U., Kyrle, P. A., Pabinger, I., Mitterbauer, M., Gisslinger, H., Knobl, P., Laczika, K., Schneider, B., Haas, O. A. and Lechner, K. (1996). Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann. Hematol., 72, 216-222.